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Despite its association with poor survival, severe tricuspid regurgitation (TR) is an underrecognized and under-treated condition; its clinical consequences being independent of age, left ventricular ejection fraction, or pulmonary artery pressures (1) . Moderate-to-severe TR is present in 1.6 million U.S individuals, yet <0.5% of this population underwent surgical tricuspid repair or replacement (2) . In patients undergoing left-sided valve surgery (LVS), concomitant tricuspid valve repair is universally recommended in the presence of severe coexistent TR (3, 4) .
Moreover, the role of surgical intervention for symptomatic severe TR late following LVS remains unclear. Isolated tricuspid valve surgery is associated with significant in-hospital mortality and poor long-term survival, especially in patients with prior mitral or aortic valve surgery (5, 6) .
In this regard, alternative minimally invasive surgical and percutaneous transcatheter treatment alternatives were recently developed in an attempt to improve the prognosis and quality of life of patients with severe TR. Novel treatment options include percutaneous annular rings, transcatheter suture bicuspidization, valved stents or heterotopic placement of transcatheter aortic valves in the vena cava (7) (8) (9) . The Forma Repair System (Edwards Lifesciences, Irvine, California) is a novel transcatheter treatment alternative for patients with severe TR and prohibitive operative risk. The device is designed to reduce severe TR by occupying the regurgitant orifice area and providing a surface for native leaflet coaptation. Herein we describe the first-in-man device experience with this novel therapeutic concept, focusing on the safety, feasibility, and preliminary efficacy in reducing severe TR and right heart failure at 30-day follow-up.
METHODS

Patient screening
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4
Patients with severe TR and symptoms of heart failure, deemed to be at high surgical risk, were considered suitable candidates for this novel device. Only patients with functional TR and without pacemaker/ICD leads or prior tricuspid surgery were considered. Following careful evaluation by a Heart Team, surgical tricuspid valve repair or replacement was deemed to be associated with an unacceptable surgical risk. All procedures were approved by Health Canada under a Special Access program, and all patients provided signed informed consent for the procedures.
TR severity was assessed by transthoracic echocardiography (TTE) in all patients. In some patients, transesophageal echocardiography (TEE) assisted in establishing the mechanism of regurgitation and the presence of multiple jets. TR severity was graded as follows: I (trace), II (mild), III (moderate) and IV (severe). The severity of TR was determined on the basis of the colour flow TR jet (large central and holosystolic jet with systolic flow reversal on hepatic veins) and the vena contracta width (≥7 mm) (10) . Cardiac computed tomography (CT) was also used to measure tricuspid annular dimensions, right ventricular diameters and the distance from the valvular annulus to the right ventricular apex. Finally, subclavian and axillary left veins were assessed by CT to ensure their size was compatible with the introducer sheath and the device.
Device concept
This transcatheter repair system is designed to reduce TR by occupying the regurgitant orifice area and providing a surface for native leaflets coaptation (Figure 1 ; Central Illustration). The device consists of a spacer and a rail which is anchored at the right ventricular apex. The spacer is a foam filled polymer balloon that passively expands via holes in the spacer shaft. Two radiopaque markers help to initially position the spacer using fluoroscopy. There are M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 fixed at the distal end in the right ventricular myocardium. The fixation mechanism consists of a 6-pronged nitinol anchor that is designed to minimize both the risk of penetration of the epicardial surface and the prong exposure in the right ventricle. It includes a retainer ring for avoiding a deep deployment of the anchor into the myocardial wall.
Procedure
Procedures were undertaken within a cardiac catheterization laboratory or hybrid operating room using general anesthesia. During all stages of device implantation, fluoroscopic guidance coupled with 2D or 3D-TEE was utilized to ensure optimal device positioning.
Following left axillary vein access, a 24F sheath was secured in place to accommodate the largest spacer size (15 mm). Right ventriculography was performed to locate the tricuspid annular plane and right ventricular apex (Figure 2A ). An ideal target location is identified to allow the device to be perpendicular to the valve plane (Figure 2A) as well as to allow all leaflets to coapt with the device. The anchor site is aimed at the right ventricular wall perpendicular to the center of the annulus. A steerable delivery catheter is positioned within the right ventricle to deliver the rail system to the ideal location ( Figure 2B) . The spacer is then tracked over the rail to the tricuspid valve plane and placed in the best position to reduce TR, assessed live with TEE. (Figure 2C/2D ) The device is then locked proximally and the excess rail length is coiled and placed within a subcutaneous pocket (Figure 3) . The entire device is fully retrievable during all stages of the procedure if needed until sheath removal.
Post-procedure and follow-up
Post-procedure, patients were admitted to a cardiology ward for clinical observation. A post-procedure TTE verified appropriate device positioning and the degree of residual TR. Rail system integrity and position were also confirmed with cardiac-CT and/or chest X-ray. First M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6 post-procedural follow-up was scheduled at 30 days along with TTE, chest X-ray, blood tests and clinical examination. Baseline characteristics of all patients, procedural and hospital outcomes as well as results of follow-up were prospectively collected. This is a descriptive study and no statistical analyses were performed.
RESULTS
Baseline characteristics
A total of 11 patients were considered potential candidates to device implantation. Of these, 4 patients were excluded due to the following reasons: decision of surgical tricuspid replacement (1 patient), concomitant gastric cancer with limited expected survival (1 patient), extremely dilated right ventricle and tricuspid annulus with very large coaptation defect (1 patient), and previous chest radiotherapy leading to a lack of sufficient subcutaneous and muscular tissue to accommodate the pocket where the excess rail length of the device system is placed (1 patient). A total of 7 patients were finally enrolled in this initial experience with the device and their baseline clinical characteristics are described in Table 1 . Mean age was 76 ± 13 years and the mean Logistic EuroSCORE was 25.7 ± 17.4%. All patients at baseline presented with a normal left ejection fraction (56 ± 5 %) and New York Heart Association (NYHA) functional class III or IV (6 patients, one patient was in class II). Pulmonary hypertension was observed in 5 patients and 5 patients had prior cardiac surgery (prior coronary artery bypass grafting in all with aortic or mitral valve surgery in 4 of them). Permanent atrial fibrillation (AF) was present in 5 patients and 6 patients had renal insufficiency, one of whom was dialysis- Table 2 summarizes procedural results and in-hospital outcomes. All patients underwent successful device implantation without procedural complications. One 12-mm device was retrieved and replaced for the largest 15 mm device during the same procedure to achieve a better result. The degree of TR was reduced intra-procedurally by at least 1 degree in all patients, and 4 patients had a reduction of 2 degrees (up to mild TR). New-onset AF appeared in 1 of the 2 patients without AF at baseline. One patient experienced several episodes of asymptomatic nonsustained ventricular tachycardia during the 24hrs following the procedure, originating from the RV and subsequently controlled with beta-blockers. In 2 other patients, frequent premature ventricular contractions (couplets or triplets) were seen during the first day post-intervention.
Procedural, in-hospital and 30-day results
One patient experienced minor bleeding related to vascular access. The same patient had a more prolonged hospitalization due to pneumonia and renal failure. The median hospital length-of-stay was 4 (3-6) days. All patients but 1 received vitamin K blockers as antithrombotic therapy following the procedure. 
DISCUSSION
This repair system is a novel transcatheter treatment option for significant TR. In this seminal series of 7 patients who were a high or prohibitive risk for surgery, all of them underwent successful device implantation without major procedural complications. All patients demonstrated improvements in TR severity, peripheral edema and NYHA functional class.
Furthermore, no significant access site or device-related complications were seen at 30-days post-procedure.
TR is not a benign condition, with a step-wise relationship between TR severity and mortality rates (11) . In patients undergoing mitral valve surgery, concomitant and untreated moderate or severe TR is associated with lower mid-term survival rates (12) . In a large series published by Nath et al (1), 1-year survival was 63.9% in those with severe TR, independent of age, biventricular systolic function, RV size and the degree of inferior vena cava dilatation.
Despite this knowledge, isolated tricuspid valve repair or replacement seldom occurs, invariably occurring concomitantly at the time of LVS (13) . Current European and AHA/ACC Guidelines M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 9 on valvular heart disease recommend concurrent TV repair at the time of LVS if the TV annulus is dilated, even if TR is found not to be severe (3, 4) . This more aggressive criterion is aimed to avoid ongoing significant TR progression during follow-up (14, 15) . Isolated tricuspid valve surgery late following initial LVS is associated with poor clinical outcomes and with in-hospital mortality rates approaching 10% (5,13). However, other studies reported better outcomes using less invasive access via a right lateral thoracotomy (16) . As such, there is an ongoing unmet clinical need for less-invasive yet effective treatment options for patients with significant TR left surgically untreated.
During recent years, and following the success of other percutaneous devices for treating structural heart disease, there is a growing interest in novel treatment paradigms for this often neglected valve lesion. Percutaneous treatment options represent an important alternative in patients deemed at high surgical risk who are refractory to medical therapy alone. However, there is currently a paucity of data relating to the feasibility, safety and results of various percutaneous tricuspid devices. A percutaneous bicuspidization of the tricuspid valve was achieved using the Mitralign system (Mitralign Inc., Tewksbury, Massachusetts). This transcatheter device, based upon pledgeted sutures and designed to plicate the mitral annulus, was successfully implanted in a patient with severe TR (7). The TriCinch System (4Tech, Dublin, Ireland) is currently being evaluated in a Phase 1 trial. It achieves a tricuspid annular reduction via a transfemoral approach by applying tension with a Dacron band anchored at the tricuspid annulus and inferior vena cava (17) . Transcatheter tricuspid valve implantation in native valves has thus far only been reported in animal models using custom-made valves (18) (19) (20) . In patients with degenerated tricuspid bioprostheses or failed surgical annuloplasty rings, the presence of this rigid structure allows safe valve implantation with a transcatheter aortic or M A N U S C R I P T
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pulmonic valve (21, 22) . The implantation of valves at the inferior cavoatrial junction or both superior and inferior vena cava was also reported with satisfactory hemodynamic outcomes, initially with a custom-made self-expandable valve and later with a Sapien XT valve (Edwards Lifesciences, Irvine, California), with associated positive RV remodeling noted in the first group of patients (8, 9, 23) . A transatrial intrapericardial tricuspid annuloplasty device, consisting of a circumferential device deployed within the pericardial space to modify tricuspid annular dimensions and reduce functional TR, was reported in an animal model (24) . Another device under preclinical development (Millipede, LLC, Ann Arbor, Michigan), is a tricuspid annuloplasty ring, which can be attached percutaneously or via minimally invasive surgery (25) . reduction from severe to moderate TR seemed sufficient to impart significant reductions in signs of right heart failure as well as improving functional status in all patients. As such, larger studies will need to be undertaken to further test the safety and efficacy of this novel device. Specific criteria for quantifying right ventricular dysfunction and pulmonary hypertension, along with novel quantitative echocardiographic imaging criteria may be required for optimizing patient selection for transcatheter tricuspid devices such as the Forma device. It is conceivable that larger than currently available spacer sizes may be required to improve echocardiographic results in patients with large non-coaptation defects and vena contracta. Some increase in the severity of TR was observed in 4 patients 30 days after the procedure. Whereas this may be related to the use of procedural TEE under general anesthesia versus TTE without anesthesia at 30 days, follow-up imaging studies are mandatory to determine the long term beneficial effects of the device.
Limitations
The evaluation of baseline and 30-day exercise (6MWT) capacity and quality of life exams were not systematically performed in all patients. Echocardiography data was not evaluated in a centralized echo core lab. No magnetic resonance imaging exams were performed to evaluate RV function and TR severity following the procedure due to the lack of data on device magnetic resonance compatibility. Finally, there was no systematic evaluation of BNP levels.
In conclusion, transcatheter reduction of secondary tricuspid valve regurgitation appears safe and feasible with this transcatheter repair system. TR reduction was observed in all patients, along with improvements in peripheral edema and functional class. Longer-term follow-up and larger studies are required to confirm these preliminary results. 
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